RecruitingNot Applicable

Evaluation of Early Home Return in Patients With Enucleation of Prostate Adenoma

France440 participantsStarted 2024-01-26

Plain-language summary

Prostate adenoma management includes, if necessary, surgical treatments: resection or vaporization by endoscopy or by open surgery in case of a very large prostate. Laser technology is a curative treatment for prostate adenoma. The minimum duration of hospitalization, in the context of enucleation prostatic endoscopy by laser, is estimated at 48 hours. The Union Clinique has developed an improved rehabilitation care pathway reducing hospitalization duration to 24 hours (one night hospitalization). This care pathway involves patient as an actor in its care but also health professionals, in particular nurses. This study is based on the hypothesis that the model developed by the Union Clinique can be translated to other healthcare establishments and that home return supervized by nurses allows reducing hospital stay length without increasing the risk of serious complications for patients

Who can participate

Age range45 Years

SexMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patient planned for endoscopic enucleation of prostate adenoma with laser * Patient with symptomatic benign prostatic hyperplasia and refractory to medical reatment and/or * Patient with benign prostatic hyperplasia complicated by chronic retention of urine and/or * Patient with benign prostatic hyperplasia complicated by prostatitis and/or * Patient with symptomatic benign prostatic hyperplasia Exclusion Criteria: * Patient living beyond the scope of care by the nurses coordination * Bedridden patient or WHO clinical condition \>2 * Patient requiring curative anticoagulation which cannot be interrupted or relayed at home by heparin * Patient with double anti-platelet aggregation who cannot be interrupted

What they're measuring

Re-hospitalizations and/or hospitalization extensions rate

Timeframe: 2 weeks

Trial details

NCT IDNCT05912764

SponsorGCS Ramsay Santé pour l'Enseignement et la Recherche

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-08-15

Contact for this trial

Philippe ROUVELLAT, MD

+ 33 5 61 37 82 93 r.rouvellat.union@gmail.com